Posted by Michael Wonder on 30 Dec 2016
Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines
29 December 2016 - What are the overall survival, quality of life, and safety benefits of recently licensed cancer medicines?
An analysis of health technology assessment reports found that new cancer drugs were associated with increased overall survival by an average of 3.43 months between 2003 and 2013, with 43% increasing overall survival by 3 months or longer, 11% by less than 3 months and 30% were not associated with an increase in overall survival. Most new cancer drugs improved quality of life, and were associated with reduced patient safety.
